Kiromic BioPharma up on filing application to start lung cancer therapy trial
03/04/2023 20:23
** Shares of gene-editing company Kiromic BioPharma Inc
KRBP.O rise 25.7% to $4.85
** Company says it has submitted its application to the U.S.
FDA to start early-stage trial in humans to evaluate its therapy
KB-GDT-01
** KB-GDT-01, or Deltacel, will be evaluated in combination
with an anti-tumor therapy for the treatment of non-small cell
lung cancer
** Despite session's gains, stock down ~9% YTD
(Reporting by Sriparna Roy)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site